Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Inhibikase Therapeutics's Enterprise Value is $161.91 Mil.
Inhibikase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-55.80 Mil. Therefore, Inhibikase Therapeutics's EV-to-EBIT ratio for today is -2.90.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Inhibikase Therapeutics (NAS:IKT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Inhibikase Therapeutics's current Enterprise Value is $161.91 Mil.
Inhibikase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-55.80 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Inhibikase Therapeutics's EV-to-EBITDA for today is:
Inhibikase Therapeutics's current Enterprise Value is $161.91 Mil.
Inhibikase Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-55.75 Mil.
Inhibikase Therapeutics's current Enterprise Value is $161.91 Mil.
Inhibikase Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Inhibikase Therapeutics's current Enterprise Value is $161.91 Mil.
Inhibikase Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.74 Mil.
Inhibikase Therapeutics's current Enterprise Value is $161.91 Mil.
Inhibikase Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics Enterprise Value Related Terms
Inhibikase Therapeutics Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IKT vs FHTX, OBIO, FULC: Enterprise Value Comparison
For the Biotechnology subindustry, Inhibikase Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's Enterprise Value falls into.
Inhibikase Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Inhibikase Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (IKT) has a Enterprise Value of $161.91 Mil as of Jun. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Inhibikase Therapeutics and its competitors.
Is Inhibikase Therapeutics' Enterprise Value too high?
Inhibikase Therapeutics' current Enterprise Value is $161.91 Mil. Overall, Inhibikase Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Enterprise Value compare to FHTX and OBIO?
Inhibikase Therapeutics' Enterprise Value of $161.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current Enterprise Value is $161.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Enterprise Value of $161.91 Mil. The current Enterprise Value is $161.91 Mil. Inhibikase Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Enterprise Value is $161.91 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
33GF Score
Get the complete analysis for IKT
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
